Chinook Therapeutics (Chinook Therapeutics) Interest Received

View and export this data going back to 2020. Start your Free Trial

What is Chinook Therapeutics Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

Chinook Therapeutics (Chinook Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chinook Therapeutics Inc (NAS:KDNY) » Definitions » Interest Received

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Fairview Avenue North, Suite 900, Seattle, WA, USA, 98109

Website

https://www.chinooktx.com

Chinook Therapeutics Inc is a clinical-stage biotechnology company. The products of the company are focused on rare, severe chronic kidney disorders. The clinical program is atrasentan, a potent and selective endothelin A receptor antagonist and currently conducting the phase 3 ALIGN trial of atrasentan for IgA nephropathy (IgAN) and the phase 2 AFFINITY basket trial for proteinuric glomerular diseases. The second product candidate, BION-1301, is an anti-APRIL monoclonal antibody and the third product candidate is CHK-336, an oral small-molecule LDHA inhibitor for the treatment of primary and idiopathic hyperoxaluria. It is incorporated in Delaware and is headquartered in Seattle, Washington.

Executives

Andrew James King	officer: Head of Renal Discovery	C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102
William Mariner Greenman	director	C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520
Eric Dobmeier	director, officer: President, CEO	C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021
Davis Jerel	director, 10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Robert Azelby	director	307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109
Mahesh Krishnan	director	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Andrew Oxtoby	officer: Chief Commercial Officer	8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005
Tom Frohlich	officer: Chief Business Officer	C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102
Eric Bjerkholt	officer: Chief Financial Officer	132 PURDURE AVENUE, KENGSINGTON CA 94708
Dolca Thomas	director	C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Srinivas Akkaraju	director	565 EVERETT AVENUE, PALO ALTO CA 94301
Alan Glicklich	officer: Chief Medical Officer	C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102
Versant Voyageurs I, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Voyageurs I Parallel, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Venture Capital Vii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104